## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.16 indicates fundamental undervaluation. Quality metrics strong (ROE 62%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($112.78)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 2)

**1. How Leadership Changes At DaVita (DVA) Have Changed Its Investment Story**
- Source: Simply Wall Street | 20251217T130759 | Neutral | Relevance: 100%
- DaVita Inc. has recently appointed Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, signaling a focus on culture, patient care, and long-term strategy amidst operational and cost pressures. While these leadership changes are more cultural than immediately catalytic, the company's expanded credit facilities provide financial flexibility to manage elevated operating costs and cyber recovery spending. Investors should consider these developments alongside rising patient care costs and reimbursement risks, which continue to influence DaVita's investment narrative and profitability.

**2. UBS reiterates Buy rating on DaVita stock, maintains $186 price target**
- Source: Investing.com | 20251215T160807 | Somewhat-Bullish | Relevance: 100%
- UBS has reaffirmed its Buy rating on DaVita (NYSE:DVA) stock, setting a price target of $186.00, which suggests a 53% upside from its current trading price. The firm cites DaVita's solid financial health and long-term operating income growth expectations of 3-7%, despite a recent earnings per share miss in Q3 2025. DaVita's growth framework includes contributions from U.S. dialysis, Integrated Kidney Care, and international business, with IKC projected to reach breakeven by 2026.

**3. DaVita Inc. (NYSE:DVA) Given Average Rating of "Hold" by Brokerages**
- Source: MarketBeat | 20251217T130356 | Neutral | Relevance: 100%
- DaVita Inc. (NYSE:DVA) has received an average recommendation of "Hold" from eight brokerages, with the average twelve-month target price set at $148.00. The company recently reported earnings of $2.51 EPS, missing analyst estimates, and its stock is currently trading down by 1.7% at $118.00. Institutional investors hold a significant portion of the stock.

**4. DaVita Inc. Stock Underperforms Monday When Compared To Competitors**
- Source: 富途牛牛 | 20251215T220820 | Somewhat-Bearish | Relevance: 100%
- DaVita Inc. (DVA) stock underperformed on Monday compared to its competitors. The article briefly mentions Unity Software (U.US) reporting strong Q4 revenue of $609 million, exceeding estimates, but also a quarterly loss of 66 cents per share.

**5. UBS reiterates Buy rating on DaVita stock, maintains $186 price target**
- Source: Investing.com Nigeria | 20251215T170754 | Neutral | Relevance: 100%
- UBS has reiterated its Buy rating on DaVita (NYSE:DVA) stock, setting a price target of $186.00, which suggests a potential 53% upside. The investment firm projects DaVita's long-term adjusted operating income growth to be in the 3-7% range, driven by contributions from U.S. dialysis operations, Integrated Kidney Care (IKC), and international business. This outlook comes despite a recent Q3 2025 earnings miss, with the company aiming for IKC segment breakeven by 2026.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 4 ($55.95M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $56M sold (4 transactions in 90 days).
2. High short interest (21.2%, 6.2 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 12.7% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +2.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.16 suggests fair value with growth premium. Forward P/E 9.3x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($56.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.5B |
| Beta | 0.99 |
| 52W Range | $113.97 - $179.60 |
| Short Interest | 21.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.16 |
| Forward P/E | 9.3 |
| Current P/E | 11.1 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.8% to 1.8% (+2.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.2pp (needs >4.0% for momentum thesis). MRS_5 at 0.9% confirms short-term momentum alignment. Below SMA200 (0.87x), long-term trend not supportive. RSI neutral at 45. OFD pattern: +DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.75% (CS: 45) | Neutral |
| RSI_14 | 45.4 | Neutral |
| MACD Histogram | 0.33 | Bullish |
| vs SMA20 | 0.998x | Below |
| vs SMA50 | 0.971x | Below |
| vs SMA200 | 0.873x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $118.38
- **Stop Loss:** $112.78 (4.7% risk)
- **Target:** $129.58 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 192
- **Position Value:** $22,728.96
- **Portfolio %:** 22.73%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*